Clinical trial NCT06502379: A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants
Official title: A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD8965 Following Single and Multiple Ascending Dose Administration to Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Healthy Participants
Keywords: Idiopathic Pulmonary Fibrosis
Lung disease
Pharmacokinetics
Food Effect
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2024-07-16
Enrollment: 163
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of AZD8965 via single and multiple ascending doses in healthy participants (including Japanese and Chinese participants), and to assess the effect of food on the safety, tolerability, and PK of orally administered AZD8965.

Detailed description: This is a first in human single and multiple ascending dose study. The study consists of 4 parts: Part 1 (single ascending dose \[SAD\]), Part 2 (multiple ascending dose \[MAD\]), Part 3A (Japanese and Chinese SAD), Part 3B (Japanese and Chinese combined SAD and MAD), and Part 4 (Food Effect).

Each study part includes a 28-day screening period and a residential period during which participants will be resident at the Clinical Unit from the day before study intervention administration (Day -1) until at least 48-72 hours after the study intervention administration.

Eligibility criteria: Inclusion Criteria:

* Healthy male and female participants (including Japanese and Chinese participants) with suitable veins for cannulation or repeated venipuncture.
* All females of childbearing potential must have a negative pregnancy test at the Screening Visit (serum) and on admission (urine) to the Clinical Unit.
* All females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception with low user dependency and their non-sterilized male partners must use a condom, to avoid pregnancy from the time of first administration of study intervention until 20 days after the last dose of study intervention. Females must not use hormonal contraceptives or hormone replacement therapy during the study.
* Females of non-childbearing potential must be confirmed at the Screening Visit by fulfilling one of the following criteria:

  1. Postmenopausal defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and without an alternative medical cause and the follicle stimulating hormone (FSH) level is in the postmenopausal range.
  2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy. Tubal ligation is not acceptable.
* Sexually active fertile male participants with partners of childbearing potential must adhere to the specified contraception methods from the time of first administration of study intervention administration until 20 days after the last dose of study intervention.
* Have a body mass index (BMI) between 18 and 30 kilogram (kg)/square meter (m2) inclusive and weigh at least 45 kg.

Part 3A and Part 3B (Japanese Participants)

* Healthy Japanese participants are eligible based on meeting all of the following:

  1. Born in Japan
  2. Have 2 Japanese biological parents and 4 Japanese grandparents.
  3. Did not live outside Japan for more than 10 years at the time of Screening. Part 3A and Part 3B (Chinese Participants)
* Healthy Chinese participants. Participants of Chinese ancestry are eligible based on meeting all of the following:

  1. Born in mainland China, Hong Kong, Macau, or Taiwan
  2. Have 2 Chinese biological parents and 4 Chinese grandparents as confirmed by the interview.
  3. Did not live outside China for more than 10 years at the time of Screening.

Exclusion Criteria:

* History of any clinically important disease or disorder which may either put the participant at risk or influence the results or the participant's ability to participate in the study.
* Chronic or ongoing gastrointestinal, respiratory, hepatic, renal disease, pancreatic disease, diabetes mellitus, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
* Chronic or ongoing neurological disorder, any clinically important past or ongoing psychiatric disorder which may confound assessment of the potential neurologic effects of this product.
* Participants with a history of hypertension or cardiovascular disease.
* Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
* Participant with chronic infections (e.g., urinary tract infection) or who are at increased risk of infection (e.g., surgery, trauma, severe dental disease, or significant infection).
* Participants with a known or suspected defect in the function of the urea cycle, or with family history of a urea cycle disorder in one or more biological relative.
* Any abnormal laboratory values and vital signs.
* Ongoing acquired or inherited immunodeficiency disorders, including but not limited to human immunodeficiency virus (HIV) or common variable immunodeficiency, or the participant is taking immune replacement therapy.
* History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD8965.

Primary outcomes:
measure: Parts 1 and 3A: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
timeFrame: SAEs: From Screening (Day -28) to 5 weeks; AEs: From Day 1 to 5 weeks
measure: Parts 2 and 3B: Number of participants with AEs and SAEs
timeFrame: SAEs: From Screening (Day -28) to 8 weeks; AEs: From Day 1 to 8 weeks.
measure: Part 4: Maximum observed drug concentration (Cmax)
timeFrame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
measure: Part 4: Area under concentration-time curve from time 0 to infinity (AUCinf)
timeFrame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
measure: Part 4: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)
timeFrame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
measure: Part 4: Time to reach maximum observed concentration (tmax)
timeFrame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
measure: Part 4: Partial area under the concentration-time curve from time t1 to time t2 [AUC(t1-t2)]
timeFrame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
measure: Part 4: Terminal elimination half-life (t½λz)
timeFrame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
measure: Part 4: Mean Residence Time (MRTinf)
timeFrame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
measure: Part 4: Apparent total body clearance (CL/F)
timeFrame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
measure: Part 4: Apparent volume of distribution based on the terminal (Vz/F)
timeFrame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
measure: Part 4: Accumulation ratio for AUC (Rac AUC)
timeFrame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
measure: Part 4: Accumulation ratio for Cmax (Rac Cmax)
timeFrame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
measure: Part 4: Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1-t2)]
timeFrame: From Day 1 (pre-dose) to Day 5
measure: Part 4: Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 [fe(t1-t2)]
timeFrame: From Day 1 (pre-dose) to Day 5
measure: Part 4: Relative bioavailability calculated as test AUC/reference AUC (Frel AUC)
timeFrame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
measure: Part 4: Relative bioavailability calculated as test Cmax/reference Cmax (Frel Cmax)
timeFrame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
measure: Part 4: Renal clearance (CLR)
timeFrame: From Day 1 (pre-dose) to Day 5
Secondary outcomes:
measure: Parts 1, 2, 3A and 3B: Maximum observed drug concentration (Cmax)
timeFrame: Parts 1 and 3A: From Day 1 (pre-dose) to Day 4 (72-hour post dose); Parts 2 and 3B: From Day 1 (pre-dose) to Day 10 (48-hour post dose)
measure: Parts 1, 2, 3A and 3B: Area under concentration-time curve from time 0 to infinity (AUCinf)
timeFrame: Parts 1 and 3A: From Day 1 (pre-dose) to Day 4 (72-hour post dose); Parts 2 and 3B: From Day 1 (pre-dose) to Day 10 (48-hour post dose)
measure: Parts 1, 2, 3A and 3B: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)
timeFrame: Parts 1 and 3A: From Day 1 (pre-dose) to Day 4 (72-hour post dose); Parts 2 and 3B: From Day 1 (pre-dose) to Day 10 (48-hour post dose)
measure: Parts 1, 2, 3A and 3B: Time to reach maximum observed concentration (tmax)
timeFrame: Parts 1 and 3A: From Day 1 (pre-dose) to Day 4 (72-hour post dose); Parts 2 and 3B: From Day 1 (pre-dose) to Day 10 (48-hour post dose)
measure: Parts 1, 2, 3A and 3B: Partial area under the concentration-time curve from time t1 to time t2 [AUC(t1-t2)]
timeFrame: Parts 1 and 3A: From Day 1 (pre-dose) to Day 4 (72-hour post dose); Parts 2 and 3B: From Day 1 (pre-dose) to Day 10 (48-hour post dose)
measure: Parts 1, 2, 3A and 3B: Terminal elimination half-life (t½λz)
timeFrame: Parts 1 and 3A: From Day 1 (pre-dose) to Day 4 (72-hour post dose); Parts 2 and 3B: From Day 1 (pre-dose) to Day 10 (48-hour post dose)
measure: Parts 1, 2, 3A and 3B: Mean Residence Time (MRTinf)
timeFrame: Parts 1 and 3A: From Day 1 (pre-dose) to Day 4 (72-hour post dose); Parts 2 and 3B: From Day 1 (pre-dose) to Day 10 (48-hour post dose)
measure: Parts 1, 2, 3A and 3B: Apparent total body clearance (CL/F)
timeFrame: Parts 1 and 3A: From Day 1 (pre-dose) to Day 4 (72-hour post dose); Parts 2 and 3B: From Day 1 (pre-dose) to Day 10 (48-hour post dose)
measure: Parts 1, 2, 3A and 3B: Apparent volume of distribution based on the terminal (Vz/F)
timeFrame: Parts 1 and 3A: From Day 1 (pre-dose) to Day 4 (72-hour post dose); Parts 2 and 3B: From Day 1 (pre-dose) to Day 10 (48-hour post dose)
measure: Parts 1, 2, 3A and 3B: Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1-t2)]
timeFrame: Parts 1 and 3A: Up to Day 2; Parts 2 and 3B: Days 1, 2, 8, 9
measure: Parts 1, 2, 3A and 3B: Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 [fe(t1-t2)]
timeFrame: Parts 1 and 3A: Up to Day 2; Parts 2 and 3B: Days 1, 2, 8, 9
measure: Parts 1, 2, 3A and 3B: Renal clearance (CLR)
timeFrame: Parts 1 and 3A: Up to Day 2; Parts 2 and 3B: Days 1, 2, 8, 9
measure: Parts 2 and 3B: Area under concentration-time curve in the dosing interval (AUCtau)
timeFrame: From Day 1 (pre-dose) to Day 10 (48-hour post dose)
measure: Parts 2 and 3B: Accumulation ratio for AUC (Rac AUC)
timeFrame: From Day 1 (pre-dose) to Day 10 (48-hour post dose)
measure: Parts 2 and 3B: Accumulation ratio for Cmax (Rac Cmax)
timeFrame: From Day 1 (pre-dose) to Day 10 (48-hour post dose)
measure: Parts 2 and 3B: Temporal Change Parameter (TCP)
timeFrame: From Day 1 (pre-dose) to Day 10 (48-hour post dose)
measure: Part 4: Number of participants with AEs and SAEs
timeFrame: SAEs: From Screening (Day -28) to 6 weeks; AEs: From Day 1 to 6 weeks
Other outcomes:
Locations:
city: Glendale
country: United States
facility: Research Site
state: California
Study officials:
References: